Romania
Industry
BMI View: Initiatives by the newly re-elected Ponta government will provide a minor boost to Romania's pharmaceutical market. However, growth potential will continue to be hindered...
2012-12-28Industry
BMI View: If approved, the latest reincarnation of Romania's healthcare reform bill would boost healthcare expenditure in the country. While mandatory contributions to healthcare funds...
2012-07-13Industry
BMI View: While the fall of Romania's government in a no-confidence vote in late April was a surprise, apart from changes in risk sentiment negatively affecting our outlook for the...
2012-05-15Industry
BMI View: Industry anger against the Romanian claw-back tax is likely to remain but in the short-term it looks like the legal actions to fight it have failed. The unpredictability of...
2012-05-02Industry
BMI View: While industry opposition to the Romanian pharmaceutical claw-back tax is still high, this has not stopped GlaxoSmithKline (GSK) from announcing new investment in the country....
2012-04-20Industry
BMI View: with a few exceptions, the attractiveness of Central And Eastern European (CEE) pharmaceutical markets has remained relatively stable in our Q312 Risk/Reward Ratings (RRRs)...
2012-04-05Industry
BMI View: The resignation of Bulgarian minister of health Stefan Konstantinov remains in line with our core scenario for this market and we maintain our previously stated view that...
2012-03-20Industry
BMI View: Governments across Central Europe have been quick to introduce drug policy reforms that aim to reduce pharmaceutical expenditure and shift the financial burden on to patients...
2012-03-12
